Copyright Bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Novo Nordisk A/S pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. This year’s sales will rise only as much as 11% while operating profit expands by 7% at most based on constant exchange rates, the Danish drugmaker said Wednesday. That compares with previous estimates of a revenue increase of as much as 14%Bloomberg Terminal and an earnings gain of up to 10%Bloomberg Terminal. The trim comes as the company reported disappointing earnings for the third quarter.
